SeqWright becomes first CSP for Agilent SureSelect Target Enrichment System

NewsGuard 100/100 Score

Agilent Technologies Inc. (NYSE: A) and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider (CSP) for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.

“We are very pleased to see SeqWright gain the status of the first CSP for SureSelect on the SOLiD platform.”

SureSelect, a research-use-only system, has been shown to greatly increase the speed and cost-efficiency of next-generation sequencing by enabling researchers to focus experiments on genomic regions of interest rather than sequencing the entire genome. The system offers optimized protocols for the Illumina Genome Analyzer and Life Technologies' AB SOLiD platforms.

"When leading genomics companies like SeqWright add SureSelect to their extensive portfolios of services, it illustrates the momentum this technology has gained in just the year and a half since its introduction," said Fred P. Ernani, Ph.D., Agilent SureSelect platform business manager. "We are very pleased to see SeqWright gain the status of the first CSP for SureSelect on the SOLiD platform."

"All of us at SeqWright are very excited to have achieved CSP status for the SureSelect system," said Fei Lu, M.D., CEO of SeqWright. "The coupling of SureSelect with our established SOLiD pipeline provides us with an unprecedented level of flexibility to address the many needs of our next-gen sequencing customers."

SOURCE Agilent Technologies Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baylor study reveals role of newly inherited DNA variants in recessive diseases